# Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir

> **NCT00976404** · PHASE2 · COMPLETED · sponsor: **Robert L. Murphy** · enrollment: 28 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **BIOLOGICAL:** DNA + HIV-rAd5 vaccine
- **DRUG:** ART intensification (raltegravir)
- **DRUG:** ART intensification (maraviroc)

## Key facts

- **NCT ID:** NCT00976404
- **Lead sponsor:** Robert L. Murphy
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2013-07
- **Final completion:** 2014-06
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2014-09-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00976404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00976404, "Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00976404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*